๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials

โœ Scribed by David G. Warr; Steven M. Grunberg; Richard J. Gralla; Paul J. Hesketh; Fausto Roila; Ronald de Wit; Alexandra D. Carides; Arlene Taylor; Judith K. Evans; Kevin J. Horgan

Book ID
116428498
Publisher
Elsevier Science
Year
2005
Tongue
English
Weight
164 KB
Volume
41
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Establishing the dose of the oral NK1 an
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting
โœ Sant P. Chawla; Steven M. Grunberg; Richard J. Gralla; Paul J. Hesketh; Cindy Ri ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 152 KB

## Abstract ## BACKGROUND The neurokininโ€1 antagonist aprepitant (EMENDโ„ข; Merck Research Laboratories, West Point, PA) has been shown to reduce chemotherapyโ€induced nausea and vomiting when it is given with a 5โ€hydroxytryptamineโ€3 receptor antagonist and dexamethasone. The current study sought to

Randomized, placebo-controlled, pilot st
Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting
โœ Jon D. Herrington; Adam D. Jaskiewicz; Juhee Song ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 151 KB

## Abstract ## BACKGROUND. The combination of palonosetron and aprepitant is safe and effective in the prevention of chemotherapyโ€induced emesis (CIE). The purpose of this pilot study was to ascertain the effectiveness of 1โ€day versus 3โ€day aprepitant in the prevention of acute and delayed nausea